Zenas BioPharma (ZBIO) Cash from Operations Growth (1y) (2024 - 2026)

Zenas BioPharma (ZBIO) Cash from Operations Growth (1y) (2024 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Oculis Holding AG 65,719.23 Bn 65,718.94 Bn - 7.14%
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 470.97 Bn 466.18 Bn 1.35 Bn 356.73%
5 Vertex Pharmaceuticals 122.29 Bn 115.05 Bn 2.59 Bn 74.39%
6 Regeneron Pharmaceuticals 69.98 Bn 61.22 Bn 3.31 Bn 3.23%
7 Belite Bio 62.06 Bn 62.06 Bn - -
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.43 Bn 34.42 Bn 959.66 Mn 158.60%
10 Zenas BioPharma 1.81 Bn 1.09 Bn - -102.95%

Historic Data

Download Data
DateValue
Mar 31, 2026 -102.95%
Dec 31, 2025 -35.95%
Sep 30, 2025 -32.41%
Jun 30, 2025 -34.83%
Mar 31, 2025 -93.96%
Dec 31, 2024 -150.35%